TY - JOUR
T1 - Telomere Dysfunction Induces Sirtuin Repression that Drives Telomere-Dependent Disease
AU - Amano, Hisayuki
AU - Chaudhury, Arindam
AU - Rodriguez-Aguayo, Cristian
AU - Lu, Lan
AU - Akhanov, Viktor
AU - Catic, Andre
AU - Popov, Yury V.
AU - Verdin, Eric
AU - Johnson, Hannah
AU - Stossi, Fabio
AU - Sinclair, David A.
AU - Nakamaru-Ogiso, Eiko
AU - Lopez-Berestein, Gabriel
AU - Chang, Jeffrey T.
AU - Neilson, Joel R.
AU - Meeker, Alan
AU - Finegold, Milton
AU - Baur, Joseph A.
AU - Sahin, Ergun
N1 - Funding Information:
This work was in part supported by the Ted Nash Long Life Foundation , Edward Mallinckrodt Jr. Foundation , and NIA RO1 grant ( R01AG047924 ), all to E.S. Histological services were supported in part by PHS grant P30DK056338 to the Texas Medical Center Digestive Diseases Center. Y.V.P. is supported by a grant from PSC Partners for Cure Canada. C.R.-A. was supported by the NIH through the Ovarian Spore Career Enhancement Program FP00000019 . A. Catic was supported by R01DK115454 and the Ted Nash Long Life Foundation, and is a CPRIT Scholar in Cancer Research ( RR140038 ). J.R.N. is the Athena Water Breast Cancer Research Scholar of the American Cancer Society ( RSG-15-088-01RMC ), and his work is supported by NCI grant CA190467 . D.A.S. is supported by the Glenn Foundation for Medical Research and grants from the NIH ( R37 AG028730 , R01 AG019719 , R21 DE027490 , and R01 DK100263 ). J.A.B. is supported by NIH grants DK098656 and AG043483 . Imaging for this project was supported by the Integrated Microscopy Core at Baylor College of Medicine with funding from NIH ( DK56338 and CA125123 ), CPRIT ( RP150578 and RP170719 ), the Dan L. Duncan Comprehensive Cancer Center , and the John S. Dunn Gulf Coast Consortium for Chemical Genomics. We thank Bill Lagor, BCM, for continuous discussions and feedback.
Funding Information:
This work was in part supported by the Ted Nash Long Life Foundation, Edward Mallinckrodt Jr. Foundation, and NIA RO1 grant (R01AG047924), all to E.S. Histological services were supported in part by PHS grant P30DK056338 to the Texas Medical Center Digestive Diseases Center. Y.V.P. is supported by a grant from PSC Partners for Cure Canada. C.R.-A. was supported by the NIH through the Ovarian Spore Career Enhancement Program FP00000019. A. Catic was supported by R01DK115454 and the Ted Nash Long Life Foundation, and is a CPRIT Scholar in Cancer Research (RR140038). J.R.N. is the Athena Water Breast Cancer Research Scholar of the American Cancer Society (RSG-15-088-01RMC), and his work is supported by NCI grant CA190467. D.A.S. is supported by the Glenn Foundation for Medical Research and grants from the NIH (R37 AG028730, R01 AG019719, R21 DE027490, and R01 DK100263). J.A.B. is supported by NIH grants DK098656 and AG043483. Imaging for this project was supported by the Integrated Microscopy Core at Baylor College of Medicine with funding from NIH (DK56338 and CA125123), CPRIT (RP150578 and RP170719), the Dan L. Duncan Comprehensive Cancer Center, and the John S. Dunn Gulf Coast Consortium for Chemical Genomics. We thank Bill Lagor, BCM, for continuous discussions and feedback. E.S. and H.A. developed the general concept, ideas, and research strategies. H.A. carried out all studies and experiments except for TAA studies and QFISH analysis, which were performed by E.S. and V.A. A. Catic and J.R.N. helped with miRNA and polysome analysis. Y.V.P. M.F. V.A. and E.S. contributed to liver studies. C.R.-A. and G.L.-B. contributed to liposomal nanoparticle studies. A.M. H.J. and F.S. helped with QFISH and TIF analysis. L.L. and J.T.C. contributed to miRNA analysis. D.A.S. E.N.-O. E.V. and J.A.B. helped with analysis of sirtuin and analysis of their targets. J.A.B. is an inventor on a patent involving the use of NAD precursors to treat liver injuries. D.A.S. is a founder, equity owner, board member, advisor to, director of, consultant to, investor in, and/or inventor on patents licensed to Vium, Jupiter Orphan Therapeutics, Cohbar, Galilei Biosciences, GlaxoSmithKline, OvaScience, EMD Millipore, Wellomics, Inside Tracker, Caudalie, Bayer Crop Science, Longwood Fund, Zymo Research, EdenRoc Sciences (and affiliates Arc-Bio, Dovetail Genomics, Claret Bioscience, Revere Biosensors, UpRNA and MetroBiotech, and Liberty Biosecurity), and Life Biosciences (and affiliates Selphagy, Senolytic Therapeutics, Spotlight Biosciences, Animal Biosciences, Iduna, Immetas, Prana, Continuum Biosciences, Jumpstart Fertility, and Lua). D.A.S. sits on the board of directors of both companies. D.A.S. is an inventor on a patent application licensed to Elysium Health. His personal royalty share is directed to the Sinclair lab.
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/6/4
Y1 - 2019/6/4
N2 - Telomere shortening is associated with stem cell decline, fibrotic disorders, and premature aging through mechanisms that are incompletely understood. Here, we show that telomere shortening in livers of telomerase knockout mice leads to a p53-dependent repression of all seven sirtuins. P53 regulates non-mitochondrial sirtuins (Sirt1, 2, 6, and 7) post-transcriptionally through microRNAs (miR-34a, 26a, and 145), while the mitochondrial sirtuins (Sirt3, 4, and 5) are regulated in a peroxisome proliferator-activated receptor gamma co-activator 1 alpha-/beta-dependent manner at the transcriptional level. Administration of the NAD(+) precursor nicotinamide mononucleotide maintains telomere length, dampens the DNA damage response and p53, improves mitochondrial function, and, functionally, rescues liver fibrosis in a partially Sirt1-dependent manner. These studies establish sirtuins as downstream targets of dysfunctional telomeres and suggest that increasing Sirt1 activity alone or in combination with other sirtuins stabilizes telomeres and mitigates telomere-dependent disorders. Telomere dysfunction is implicated in the promotion of tissue damage and fibrosis through mechanisms that are incompletely understood. Amano et al. show that telomere dysfunction in liver tissue downregulates sirtuins through p53-dependent mechanisms. Increasing NAD(+) stabilizes telomeres, dampens DNA damage response, and improves telomere-dependent fibrosis in a partially Sirt1-dependent manner.
AB - Telomere shortening is associated with stem cell decline, fibrotic disorders, and premature aging through mechanisms that are incompletely understood. Here, we show that telomere shortening in livers of telomerase knockout mice leads to a p53-dependent repression of all seven sirtuins. P53 regulates non-mitochondrial sirtuins (Sirt1, 2, 6, and 7) post-transcriptionally through microRNAs (miR-34a, 26a, and 145), while the mitochondrial sirtuins (Sirt3, 4, and 5) are regulated in a peroxisome proliferator-activated receptor gamma co-activator 1 alpha-/beta-dependent manner at the transcriptional level. Administration of the NAD(+) precursor nicotinamide mononucleotide maintains telomere length, dampens the DNA damage response and p53, improves mitochondrial function, and, functionally, rescues liver fibrosis in a partially Sirt1-dependent manner. These studies establish sirtuins as downstream targets of dysfunctional telomeres and suggest that increasing Sirt1 activity alone or in combination with other sirtuins stabilizes telomeres and mitigates telomere-dependent disorders. Telomere dysfunction is implicated in the promotion of tissue damage and fibrosis through mechanisms that are incompletely understood. Amano et al. show that telomere dysfunction in liver tissue downregulates sirtuins through p53-dependent mechanisms. Increasing NAD(+) stabilizes telomeres, dampens DNA damage response, and improves telomere-dependent fibrosis in a partially Sirt1-dependent manner.
KW - liver disease
KW - metabolism
KW - p53
KW - sirtuins
KW - telomeres
UR - http://www.scopus.com/inward/record.url?scp=85066236523&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066236523&partnerID=8YFLogxK
U2 - 10.1016/j.cmet.2019.03.001
DO - 10.1016/j.cmet.2019.03.001
M3 - Article
C2 - 30930169
AN - SCOPUS:85066236523
SN - 1550-4131
VL - 29
SP - 1274-1290.e9
JO - Cell Metabolism
JF - Cell Metabolism
IS - 6
ER -